Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada
Introduction Several new oral drug classes for type 2 diabetes (T2DM) have been introduced in the last 20 years accompanied by developments in clinical evidence and guidelines. The uptake of new therapies and contemporary use of blood glucose-lowering drugs has not been closely examined in Canada. T...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-11-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Online Access: | https://drc.bmj.com/content/10/6/e002995.full |
| _version_ | 1811180230242467840 |
|---|---|
| author | Ken Bassett Colin R Dormuth Wade Thompson Greg Carney Jason D Kim Cait O'Sullivan Josh Levin |
| author_facet | Ken Bassett Colin R Dormuth Wade Thompson Greg Carney Jason D Kim Cait O'Sullivan Josh Levin |
| author_sort | Ken Bassett |
| collection | DOAJ |
| description | Introduction Several new oral drug classes for type 2 diabetes (T2DM) have been introduced in the last 20 years accompanied by developments in clinical evidence and guidelines. The uptake of new therapies and contemporary use of blood glucose-lowering drugs has not been closely examined in Canada. The objective of this project was to describe these treatment patterns and relate them to changes in provincial practice guidelines.Research design and methods We conducted a longitudinal drug utilization study among persons with T2DM aged ≥18 years from 2001 to 2020 in British Columbia (BC), Canada. We used dispensing data from community pharmacies with linkable physician billing and hospital admission records. Laboratory results were available from 2011 onwards. We identified incident users of blood glucose-lowering drugs, then determined sequence patterns of medications dispensed, with stratification by age group, and subgroup analysis for patients with a history of cardiovascular disease.Results Among a cohort of 362 391 patients (mean age 57.7 years old, 53.5% male) treated for non-insulin-dependent diabetes, the proportion who received metformin monotherapy as first-line treatment reached a maximum of 90% in 2009, decreasing to 73% in 2020. The proportion of patients starting two-drug combinations nearly doubled from 3.3% to 6.4%. Sulfonylureas were the preferred class of second-line agents over the course of the study period. In 2020, sodium-glucose cotransporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists accounted for 21% and 10% of second-line prescribing, respectively. For patients with baseline glycated hemoglobin (A1C) results prior to initiating diabetic treatment, 41% had a value ≤7.0% and 27% had a value over 8.5%.Conclusions Oral diabetic medication patterns have changed significantly over the last 20 years in BC, primarily in terms of medications used as second-line therapy. Over 40% of patients with available laboratory results initiated T2DM treatment with an A1C value ≤7.0%, with the average A1C value trending lower over the last decade. |
| first_indexed | 2024-04-11T06:47:43Z |
| format | Article |
| id | doaj.art-46a09c638a5e4aba850917aa777a3b48 |
| institution | Directory Open Access Journal |
| issn | 2052-4897 |
| language | English |
| last_indexed | 2024-04-11T06:47:43Z |
| publishDate | 2022-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Diabetes Research & Care |
| spelling | doaj.art-46a09c638a5e4aba850917aa777a3b482022-12-22T04:39:18ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972022-11-0110610.1136/bmjdrc-2022-002995Treatment pattern trends of medications for type 2 diabetes in British Columbia, CanadaKen Bassett0Colin R Dormuth1Wade Thompson2Greg Carney3Jason D Kim4Cait O'Sullivan5Josh Levin6Therapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaTherapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaTherapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaTherapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaTherapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaTherapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaTherapeutics Initiative, The University of British Columbia, Victoria, British Columbia, CanadaIntroduction Several new oral drug classes for type 2 diabetes (T2DM) have been introduced in the last 20 years accompanied by developments in clinical evidence and guidelines. The uptake of new therapies and contemporary use of blood glucose-lowering drugs has not been closely examined in Canada. The objective of this project was to describe these treatment patterns and relate them to changes in provincial practice guidelines.Research design and methods We conducted a longitudinal drug utilization study among persons with T2DM aged ≥18 years from 2001 to 2020 in British Columbia (BC), Canada. We used dispensing data from community pharmacies with linkable physician billing and hospital admission records. Laboratory results were available from 2011 onwards. We identified incident users of blood glucose-lowering drugs, then determined sequence patterns of medications dispensed, with stratification by age group, and subgroup analysis for patients with a history of cardiovascular disease.Results Among a cohort of 362 391 patients (mean age 57.7 years old, 53.5% male) treated for non-insulin-dependent diabetes, the proportion who received metformin monotherapy as first-line treatment reached a maximum of 90% in 2009, decreasing to 73% in 2020. The proportion of patients starting two-drug combinations nearly doubled from 3.3% to 6.4%. Sulfonylureas were the preferred class of second-line agents over the course of the study period. In 2020, sodium-glucose cotransporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists accounted for 21% and 10% of second-line prescribing, respectively. For patients with baseline glycated hemoglobin (A1C) results prior to initiating diabetic treatment, 41% had a value ≤7.0% and 27% had a value over 8.5%.Conclusions Oral diabetic medication patterns have changed significantly over the last 20 years in BC, primarily in terms of medications used as second-line therapy. Over 40% of patients with available laboratory results initiated T2DM treatment with an A1C value ≤7.0%, with the average A1C value trending lower over the last decade.https://drc.bmj.com/content/10/6/e002995.full |
| spellingShingle | Ken Bassett Colin R Dormuth Wade Thompson Greg Carney Jason D Kim Cait O'Sullivan Josh Levin Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada BMJ Open Diabetes Research & Care |
| title | Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada |
| title_full | Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada |
| title_fullStr | Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada |
| title_full_unstemmed | Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada |
| title_short | Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada |
| title_sort | treatment pattern trends of medications for type 2 diabetes in british columbia canada |
| url | https://drc.bmj.com/content/10/6/e002995.full |
| work_keys_str_mv | AT kenbassett treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada AT colinrdormuth treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada AT wadethompson treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada AT gregcarney treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada AT jasondkim treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada AT caitosullivan treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada AT joshlevin treatmentpatterntrendsofmedicationsfortype2diabetesinbritishcolumbiacanada |